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Abstract  
Background and Aims 
The burden on family members of those who are dependent on illicit drugs is largely unidentified 
despite the presence of significant negative financial, health and social impacts.  This makes it 
difficult to provide appropriate services and support.  This study aimed to assess the preferences for 
treatment attributes for heroin dependence among family members affected by the drug use of a 
relative and to obtain a measure of the intangible economic benefit.  
Design 
Discrete choice experiment. Data were analysed using mixed logit which accounted for repeated 
responses. 
Setting 
Australia 
Participants 
Eligible participants were Australian residents of 18+ years of age with a relative with problematic 
drug use.  Complete data on 237 respondents were analysed; 21 invalid responses were deleted.   
Measurements 
Participant preference for likelihood of staying in treatment, family conflict, own health status, 
contact with police and monetary contribution to a charitable organisation providing treatment.  
Findings  
All attributes were significant, and the results suggest there was a preference for longer time in 
treatment, less family discord, better own health status, less likelihood of their relative encountering 
police, and while they were willing to contribute to a charity for treatment to be available, they prefer 
to pay less not more. In order of relative importance, participants were willing to pay an additional 
$4.46 (95% CI 3.33-5.60) for treatment which resulted in an additional 1% of heroin users staying in 
treatment for longer than 3 months, $42.00 (95% CI 28.30-55.69) to avoid 5 days per week of family 
discord, $87.94 (95% CI 64.41-111.48) for treatment options that led to an improvement in their own 
health status, and $129.66 (95% CI 53.50-205.87) for each 1% decline in the chance of police contact.  
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Conclusions  
Drug treatment in Australia appears to have intangible benefits for affected family members. Families 
are willing to pay for treatment which reduces family discord, improves their own health, increases 
time in treatment and reduces contact with police.  
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Background:  
Family members are often the main source of support for those who are dependent on illicit drugs 
or alcohol, but they have to a large extent remained a ‘hidden’ or neglected population(1). Family 
members have remained hidden in terms of a lack of awareness of both the amount of support they 
provide and the impact of their relative’s drug and alcohol use (hereafter the word drug refers to 
both drugs and alcohol). Family members are often overlooked at both a policy and service level, 
with few services designed to support family members who have a drug using relative. This is 
despite the fact that providing this support can lead to significant financial, psychological and 
physical health improvements (2, 3). Other research has highlighted the emotional and 
psychological impact of drug use for family members as a result of fear, shame, guilt and anger(3), 
often resulting in isolation, anxiety, depression and poor health(4-6). Although difficult to quantify 
the precise number of family members directly affected, given that around 1 in 20 Australians are 
dependent or have substance abuse problems(7) and every person with substance misuse issues will 
affect, on average, two close family members to the extent that they require support from primary 
healthcare services(8), this suggests a sizeable burden associated with the substance abuse of a 
relative. While there have been cost of illness studies (see (9) for a review) and studies investigating 
the impact of drug use on the quality of life of family members (10, 11), the data and methods to 
quantify how family members value successful drug treatment have to date been limited. Much of 
the research to date has focused on using qualitative methods to explore the impact of drug use on 
family members(3, 12). However, the data and methods to quantify and value the impact for family 
members of successful drug treatment are limited(13, 14)and there are no clear recommendations 
on how best to support family members(15). Clearly, if we are to better support family members 
then more needs to be done to fully understand the benefits drug treatment has not only for the drug 
user but also for their family members.  
One way to understand those benefits to family members is to measure how they might choose 
between alternative treatment programs for their drug dependent relative; programs that might vary 
in their implementation and efficacy at treating drug dependency. Discrete choice experiments (DCE) 
are one way in which such an assessment can be conducted, allowing comparisons to be made 
between existing treatment programs and those which might be conceivably introduced.    
The DCE approach uses the choices participants make between hypothetical, but realistic, options to 
understand the preferences motivating those choices. Underpinning this approach is Lancaster’s 
random utility theory (RUT) which assumes that individuals make choices which give them the 
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highest level of satisfaction(16) and that individuals derive wellbeing (utility) not from a treatment 
itself but rather from the attributes (characteristics) of that good (treatment)(17, 18). Thus, in choosing 
between options in a DCE, the respondent is revealing the alternative they prefer on the basis that it 
yields the highest utility from among the options on offer. DCEs have been extensively used in health 
to explore patient preferences for treatment options, evaluate trade-offs between outcomes and 
experience and to develop priority setting frameworks(19) and to quantify the intangible burden 
experienced by carers in schizophrenia and Alzheimer’s disease(20, 21). 
The aim of this study was to 1) conduct a DCE to assess the preferences for the characteristics and 
outcomes of treatment for heroin dependence among family members affected by the drug use of a 
relative and 2) to obtain a measure of the intangible economic benefit of treatment.  
Methods  
 Selecting attributes and levels   
Steps in a DCE include conceptualising the problem, framing the question, selecting the attributes 
and the levels over which they are described, developing an experimental design, collecting (via 
survey) and analysing the data(18, 19, 22-25). Attributes and levels were selected following a 
literature review focused on studies of family members affected by the drug use of a relative and 
consultation with experts in the field of drug family support. The applicability, wording and levels of 
potential attributes were tested in a semi-structured qualitative focus group discussion with family 
members (N=4) affected by the drug use of a relative. The discussions with family members were 
recorded and the key points collated with those obtained from consultations with the experts, and the 
wording of attributes were refined accordingly.  This involved small changes in wording. 
In any DCE the choice of the number of attributes (and their levels) is key – too many, especially in 
a complex situation, and the cognitive burden may result in the use of simplifying heuristics. 
However, too few and the participants may discount the survey as being unrealistic(23) and important 
attributes remain unquantified. Ultimately, five attributes were selected: days per week of family 
conflict, health status of the person (family member) completing the survey, the likelihood of the 
relative who requires treatment for drug use staying in treatment for three months, change in the 
amount of the relative’s contact with police, and the family members’ willingness to donate to a 
charity for treatment to be available (Tables 1 and 2). 
Having selected the attributes (5) and their levels (2-4) and the number of alternatives (3) which 
comprise the scenarios, the next step was to generate the statistical design. The full design of all 
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possible combinations of attributes and their levels was deemed too large to administer to participants, 
therefore a fractional blocked design of 64 (8 blocks of 8 scenarios) with 3 alternatives (two 
unlabelled hypothetical alternatives and a neither alternative) was generated using the NGENE 
software(26).   
Insert Tables 1 and 2 about here 
Within the survey, participants were asked to complete two sets of scenarios: one where the person 
to receive the treatment was their relative and the other where the person to receive treatment was a 
stranger. While the wording of the attributes changed slightly to accommodate these differences, the 
choice sets seen by the respondents were identical for the two sets of scenarios. Prior to seeing their 
first-choice set, each respondent saw a description of the context (see Supplementary material for the 
context and background story).  
The demographics and characteristics collected on participants included: age, relationship to person 
using drugs, gender, education, health status, income, marital status, Family Member Impact 
Questionnaire(12) and their quality of life (AQoL4)(27).  The choice of the AQoL 4 follows from 
concerns over the insensitivity of the EQ-5D and SF-6D in detecting changes in HRQOL in people 
with mental health and drug dependencies (28,29). The AQoL 4 (Assessment of Quality of Life 4) 
is a short, easy to administer and well validated tool for estimating Qol (28).  This tool, in addition, 
to addressing physical health dimensions includes non-physical dimensions such as relationships, 
mental health and the senses.  It also applies a greater weight to social disabilities which is an 
important consideration in this population. 
 Information collected from participants about their relative included: age, main drug of concern, 
years of drug use, treatment, overdose, and known criminal histories. The text was piloted during 
the focus group.  The survey tool, hosted on the UNSW website was KeySurvey, and the analyse 
were conducted using NLogit (Limdep, Econometric Software Inc).   
Participant recruitment 
Participants were recruited through family drug support agencies and advertising through their social 
media (e.g. Twitter, Facebook) and completed the survey on-line. To be eligible, participants were 
required to be at least 18 years of age, reside in Australia, and to have a relative with problematic 
drug use. The original intent was to focus on families where heroin was the main drug of concern. 
However, following consultation with family members, support agencies and experts in the drug field 
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it was decided to broaden the focus to recruit from those affected by any drug use as families often 
did not know which drug was most of concern, or it changed with availability of the drug.  
Analysis  
Within the RUT framework, the utility that an individual i derives from choosing alternative j 
(treatment program A, B or Neither) can be expressed as  
𝑈𝑈𝑖𝑖𝑖𝑖 = 𝑋𝑋𝑖𝑖𝑖𝑖𝛽𝛽 + 𝜀𝜀𝑖𝑖𝑖𝑖; 𝑖𝑖 = 1, 2, … ,𝑛𝑛𝑖𝑖 
where  𝑈𝑈𝑖𝑖𝑖𝑖  is the observed utility,  𝑋𝑋𝑖𝑖𝑖𝑖 is a vector of variables representing attributes of alternative j, 
and 𝛽𝛽 is a vector of coefficients. 𝑋𝑋𝑖𝑖𝑖𝑖𝛽𝛽 is the deterministic component, 𝜀𝜀𝑖𝑖𝑖𝑖 is the random 
component(29) and 𝑛𝑛𝑖𝑖 is the number of participants. In this study, the deterministic component is 
represented as: 
𝑋𝑋𝑖𝑖𝑖𝑖𝛽𝛽 = 𝛽𝛽1(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡) + 𝛽𝛽2(𝑓𝑓𝑡𝑡𝑡𝑡𝑖𝑖𝑓𝑓𝑓𝑓_𝑐𝑐𝑐𝑐𝑡𝑡𝑓𝑓𝑓𝑓𝑖𝑖𝑐𝑐𝑡𝑡) + 𝛽𝛽3(𝑐𝑐𝑜𝑜𝑡𝑡_ℎ𝑡𝑡𝑡𝑡𝑓𝑓𝑡𝑡ℎ) + 𝛽𝛽4(𝑐𝑐𝑡𝑡𝑖𝑖𝑡𝑡𝑖𝑖𝑡𝑡𝑡𝑡𝑓𝑓𝑖𝑖𝑡𝑡𝑓𝑓) + 𝛽𝛽5(𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑐𝑐𝑐𝑐𝑡𝑡𝑖𝑖𝑐𝑐𝑡𝑡) 
The dependent variable represents the probability of choosing one alternative over another, given 
their respective attributes and levels. The independent variables are the attributes and their levels. 
The attributes with categorical levels (own health status and days per week of family conflict) and 
demographic variables were effects coded, which means the constant is not confounded with the 
grand mean(30). All other attributes were treated as continuous. The drug of concern of the relative 
was classified as either: 1) opioids, including heroin; 2) alcohol; 3) stimulants; or 4) cannabis.  
A constant was specified for the ‘neither’ option permitting the measurement of the average effect on 
utility for the tendency of choosing the ‘Neither’ option over treatment program A or B (note: an 
alternate specific constant was applied to treatment B, to explore for response differences between 
treatment A and B; it was not significant thus removed in further analyses).  
Initial MNL(17) models were estimated using a panel specification to account for correlated choices 
by individuals, as each person completed eight choice tasks (or 16 when the relative and stranger data 
sets were pooled). Separate analysis was conducted on the responses pertaining to a relative (family) 
and then for those pertaining to a stranger (stranger). They were then analysed as a single data set, 
with a dummy variable to account for the survey version. As there were only small differences 
between the results from the two versions (and the survey version dummies were not significant), the 
results presented below focus on the outcomes for the combined analysis (family and stranger version 
specific results are provided in Supplementary material). 
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Given the nature of the topic, heterogeneity of responses across the sample would be expected. This 
was explored using a mixed logit (MX) model with all attributes and the constant specified as a 
normal distribution, 1000 Halton draws and a panel specification(29, 31). (The constant was treated 
as a random parameter as it captures preferences between treatment (A/B) and neither (it is the 
alternative specific constant) and these are expected to vary between individuals). We tested for the 
sources of heterogeneity, potentially as exhibited by similarities between respondent characteristics 
and how they responded to the programs on offer. To identify potential covariates, a MX model 
with no covariates was estimated and the resulting choice probabilities at the individual level were 
regressed on relevant covariates using an ordinary least squares (OLS) specification. The 
sociodemographic characteristics (e.g. age, income etc) and other covariates were then list wise 
excluded(32). Following work by others, a decision was made to estimate a parsimonious model 
which retained only those variables with a p< 0.20 (32). 
When a monetary attribute is included in a DCE, as was the case here, it is possible to estimate the 
marginal willingness to pay (WTP) values for any given attribute by estimating its marginal rate of 
substitution (MRS) with respect to cost(25, 33, 34). The MRS is estimated as the ratio of the 
coefficients of the attributes of interest to the negative of the coefficient of the cost attribute(30). 
This was estimated for all statistically significant non-monetary attributes. The WTP estimates and 
the 95% confidence intervals were calculated using the delta method(35, 36). 
The study was approved by the Human Research Ethics Committee of UNSW Sydney (UNSW HREC 
reference: # HC14129). As survey participation was anonymous consent was implied based on each 
individual’s completion of the survey. 
Results  
The survey was conducted July through November 2014. A total of 579 people logged onto the 
website and completed the consent, with 258 participants completing the survey. Data from 237 
participants were analysed; 21 were excluded due to data discrepancies (such as invalid answers to 
open ended questions, ages which were not plausible combined with choosing the same treatment 
option for all questions). Care was taken to assess each person’s total responses before a decision was 
made to remove any data.  Participants did not receive any compensation.   
Sample descriptive characteristics  
The mean age of participants was 46.0 (SD 14.87) years, they were predominantly female (86.1%) 
(of which 52% were mothers), most were married/de facto (64.6%), 44% had a university degree, and 
most were employed (67%) or retired (13%) with only 5.5% reporting being unemployed. In 
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comparison, in the general population is 50.7% female, 48.1% married or in a defacto relationship; 
19.7% have completed year 10 or less, 20% completed a diploma, while 22% have a university 
degree. The sample was not selected to be representative of the general population, but rather recruit 
family members affected by the drug use of a relative. Half of the participants (49.8%) were parents 
of a person who was using drugs, while 15.2% were partners and 5.9% were siblings (the remainder 
were grandparents or other family members) (Table 3). There were no significant differences in 
respondent demographics across the eight blocks. 
Insert Tables 3 & 4 about here 
In terms of the characteristics of the relative who was using drugs (Table 4), the mean number of 
years of use was 13.0 (SD 9.46), 63% had at least one treatment episode, less than a quarter had a 
known criminal history, most either lived in their own accommodation (35%) or in the same 
household as the respondent (36%). The drugs of main concern were stimulants (34.2%), alcohol and 
cannabis (22.8% respectively), and opioids (20.3%). Almost one third of respondents (28.3%) 
reported their relative had previously had an overdose, while a similar number (31.2%) reported they 
did not know if their relative had suffered an overdose.  
Analysis of the DCE 
In the initial MNL model the constant on the ‘neither’ option was positive and significant, this 
suggested that participants would rather not choose either treatment A or B. All coefficients were 
statistically significant (Table 5 and Supplementary material). The signs on the coefficients for the 
attributes were generally as expected. That is, participants preferred: that the person using heroin had 
a greater likelihood of staying in treatment longer than three months; fewer days of family conflict 
than more; that their own health status improves; that the person using drugs was less likely to come 
into contact with police; and to donate less rather than more to charities for drug treatment. The one 
unexpected finding was that participants preferred two days per week of family conflict compared to 
one day (base).   
Insert Table 5 about here 
As expected, the MX models demonstrated significant heterogeneity with highly significant standard 
deviations on the attribute coefficients. In the model with no covariates included, the constant was 
not significant (Model 2). Notably, all coefficients remained highly significant on all attributes. 
Significant covariates identified in the linear analysis of choice probabilities (not shown) were 
stimulants, alcohol and opioids as main drugs of concern, relative ever been in treatment for drug or 
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alcohol dependence, respondent never married, and number of dependent children in the respondent’s 
household.  
Model 3 included these covariates.  Here, the coefficient on the constant was highly significant and 
negative, indicating that treatment choices A and B were preferred to no treatment option. In addition, 
there was a strong preference for treatment longer than three months, and all else equal, two days per 
week of family conflict was preferred to one, but four days were less preferred and the larger 
(negative) coefficient on six days suggested it was marginally less preferred than four. Once again, 
an improvement in respondent’s own health status was preferred, as was less contact by the relative 
with police. Four covariates were significant (main drugs of concern are stimulants or opioids, those 
who have never been married, and number of dependent children). The positive and significant 
coefficient on stimulants would indicate that compared to cannabis (base), those for whom stimulants 
are a main drug of concern would choose a treatment option over the neither option, whereas for those 
whose relatives’ main drug of concern was opioids, it was less likely a treatment option was chosen. 
Similarly, those family members with more dependent children are less likely to choose a treatment 
option, whereas those who have never been married are more likely.  
Insert Figure 1 about here 
Insert Table 6 about here 
Willingness to pay 
Before examining the marginal willingness to pay, Figure 1 presents the distribution of the values for 
‘contribution to a charity’ among all the choices made by respondents. The median choice is $30. The 
marginal WTP for each treatment attribute was estimated based on the results from Model 3 and are 
shown in Table 6. Participants were willing to pay an additional $4.46 (95% CI 3.33-5.60) per week 
for treatment which resulted in an additional 1% of heroin users staying in treatment for longer than 
3 months, an additional $42.00 (95% CI 28.30-55.69) to avoid 5 days per week of family discord 
(from 6 days to 1) and $87.94 (95% CI 64.41- 111.48) for treatment options that led to an 
improvement of their own health status. The most valued treatment attribute was that of decreasing 
police contact, with participants willing to pay an additional $129.66 (53.50-205.87) for a 1% 
decrease.  
Discussion  
The aim of this study was to determine which characteristics and outcomes from treatment for heroin 
dependence are important for family members and to estimate their WTP for associated 
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improvements. To our knowledge, this study is unique in both its focus and in its use of a DCE to 
quantify the preferences of family members for treatment for heroin dependence. While the 
perspective of the person using drugs is, of course highly relevant, there is a need to also understand 
the perspective of family members who provide support to them(1, 6). In addition to direct costs to 
family members in relation to costs of crime, other day-to-day costs and any negative impact on their 
employment(37) there is evidence that a lack of recognition and support may result in poor health 
status of family members(4, 5).   
Our analysis finds that among those who have a relative who is (or has been) drug dependent, there 
is a preference for longer time in treatment, less family discord, better own health status, less 
likelihood of coming in contact with police, and while they are willing to contribute to a charity for 
treatment to be available, they would prefer to pay less not more. While we explored whether those 
preferences differed for own family members or a stranger, our analysis found little difference 
between them. It may be that for some families having had protracted experiences with their own 
family member’s dependency meant they were willing to contribute for others to benefit, indicating 
an implied positive externality. Alternatively, it may be that participants did not understand/ read the 
instructions and interpreted the survey as always pertaining to treatment for their family member. 
The results suggest differences across respondents in the impact of attributes on treatment choices, 
but it was not possible to identify all the factors which explained those differences. Covariates of 
significance included the drug of concern, the number of dependent children and having never 
married. In terms of drug of concern, the coefficient on stimulants was positive, suggesting that 
participants preferred treatment A or B compared to the neither option. However, the results suggest 
the opposite for those where opioids were the main drug of concern. The reasons for this difference 
are not apparent, however these data were collected at a time of increasing community concern around 
the perceived harms of methamphetamine(38) including frequent reports of violent behaviours and 
psychosis. This may have resulted in a preference for treatment. Nevertheless, it is the lack of 
preference for treatment for opioid use which is puzzling. It may be that if families have had a lengthy 
experience with opioids they no longer view current treatment as effective, although it was not 
possible to explore this. 
The significance of the number of children, and never being married may reflect the role of family 
structure in influencing preferences for treatment options. While there was a clear preference for one 
day of family discord compared to four or six days, an unexpected finding was the apparent preference 
for two days per week compared to one day. It may be that this was a proxy for engagement with 
12 
 
family (given not all relatives resided with the family member participants), i.e. that it is better to see 
the family member even if there is discord during the contact.   
Despite evidence in the literature that a longer duration in treatment is more likely to result in a 
positive treatment response (39) whether it be abstinence or continuing medicated treatment (opioid 
agonist treatment or medicated treatment for alcohol dependence) the WTP for increasing the number 
of people staying in treatment longer was the smallest.   
Reflecting the disutility of having a drug dependent relative, participants were willing to pay a 
substantial amount ($87.94 (95% CI 64.41-111.48)) for a program which resulted in an 
improvement in their own health status. This is in line with previous research which has found that 
there is poorer health and greater utilisation of healthcare services among family members affected 
by the drug use of a relative(4, 5). A program which results in less contact with law enforcement is 
highly preferred and valued at a WTP of $129.68 (95% CI 53.50-205.87) to have a 1% decrease in 
police contact. In light of the fact that weekly opioid substitution treatment may cost $35 to $70 per 
week(40), residential rehabilitation can cost upwards of $150 per day for stays that may range 
between 30 days to 12 months, and legal fees and court costs may be substantial these WTP 
amounts appear reasonable if somewhat conservative given that they are bounded by the ranges on 
the cost attribute provided to the respondents. Additionally, contingent valuation studies have found 
that families are willing to pay €307 (AUD 485) per month (indefinitely treatment for alcohol 
dependence which is 50% effective  (41)  and CHF 449 (AUD 625) (42) for treatment for alcohol 
dependence.  
As in any research there are limitations. The sample size of 237 may seem small however, there is 
no agreed rule on the sample size required for a DCE(43-45). Research has shown that model 
estimate precision increases rapidly at sample sizes greater than 150 and then flattens out at around 
300 respondents. This study, with a sample of 237 respondents completing eight scenarios, is well 
within this estimate. Moreover, simulation studies have shown that model stability and estimate 
precision requires 20 observations per choice set(45). Our DCE comprised 64 choice sets, requiring 
1,280 observations for model estimation. With 237 respondents completing 8 choice sets each we 
had 1,896 total observations, or just under 30 per choice set. In addition, our sample was large 
enough to allow us to estimate the relationships of interest with sufficient power.   
The representativeness of the sample - in terms of the participants and their relatives - is unknown.  
The sample was recruited through agencies that have been established by and for families affected by 
the drug dependence of a relative and through their social media methods. As such they may have 
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been more motivated to complete the survey and the results may not be generalisable to all family 
members of those dependent on drugs.  Further, any limiting recruitment to only heroin use was not 
possible given the frequent lack of knowledge of family members as to the main drug of concern, the 
extent of polydrug use and the switching of drugs contingent on availability.  
There were other attributes highlighted as important during the literature review, such as 
stigmatisation and impact to own social life but these variables were not as salient in the focus group 
discussion. It was also difficult to develop meaningful levels for those attributes. While financial 
concerns were very common among family members it was felt that including both a WTP attribute 
and attempting to directly capture financial burden would be confusing for the respondent thus a 
decision was made to include only the willingness to contribute to a charity.   
 
Conclusion  
There is clear evidence that family members experience significant negative effects as a result of the 
drug or use of a relative(2, 3). To date, drug treatment has often only been considered beneficial for 
the individual receiving treatment. This study shows that drug treatment also has intangible benefits 
for affected family members. Moreover, family members are willing to pay for treatment that results 
in certain outcomes, such as less family discord, an improvement to one’s own health, longer time 
spent in treatment and reduced contact with the police.  
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Table 1: Attributes and the levels 
Attribute Explanation Levels 
Likelihood of staying in 
treatment ≥ 3 months 
 
Number of heroin users 
who stay in treatment 
longer than 3 months 
40 out of 100 
50 out of 100 
60 out of 100 
70 out of 100 
Conflict Days of conflict per week 
between drug user and 
their family  
1 day per week 
2 days per week 
4 days per week 
6 days per week 
Health The health status of the 
family member of the 
person using drugs 
Stays the same 
Improve 
 
Criminality 
 
Percentage decrease in 
relative’s contact with 
police as a result of 
criminal behaviour 
10% 
20% 
30% 
40% 
WTP The weekly contribution 
amount the participant is 
willing to donate to charity 
 
$10 
$30 
$60 
$100 
 
 
Table 2: Example of a profile presented to respondent.  
Characteristic Option A Option B 
Number of heroin users who stay in 
treatment longer than 3 months 40 out of 100 70 out of 100 
Days of conflict per week with drug 
using relative 4 2 
Own health status  Stays the same Improves 
Percentage decrease in relative's 
contact with police 20% 40% 
Your weekly payment to a charity for 
drug treatment $50 $100 
Please select the option that represents your most preferred choice  
Option A   □  
Option B   □  
Neither A or B  □ 
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Table 3: Characteristics of the survey respondent  
 All (N=237) Percent / (SD) 
Age (mean/SD) 46.0  (14.87) 
Gender Female N/% 221 86.1 
Marital Status N/%   
Single  33 13.9 
Married/de facto 153 64.6 
Divorced/Sep  42 17.7 
Not stated 9 3.8 
Level of education   
= < year 10  33 13.9 
Year 12  28 9.7 
TAFE/Diploma/ other  69 29.1 
University  105 44.3 
Employment   
FT/ PT  159 67.1 
Student 17 7.2 
Retired 28 13 
Unemployed  13 5.5 
Homemaker  20 8.4 
Number of dependent children  0.75 (range 0 to 6)  (1.2) 
Relationship the drug user is to the 
respondent   
  
Parent 14 5.9 
Child  118 49.8 
Spouse/Partner  36 15.2 
Other  69 29.1 
 
Table 4: Characteristics of the person using drugs  
Drug user information as provided by 
respondent  
All Percent / SD 
Age  32.45 SD 11.18 
Years used drugs 13.0 SD 9.46 
Drugs of main concern    
Opioids 48 20.3 
Alcohol 54 22.8 
Stimulants 81 34.2 
Cannabis  54 22.8 
Ever received Treatment: Yes  160 63.3 
Overdosed Yes    
     Yes 67 28.3 
     No  96 40.5 
    Don’t know 74 31.2 
Previously committed non-drug offences   57 24.1 
Where family member resides   
Same household  93 36 
Own accommodation  92 35 
Homeless  2 7 
Parental home 18 6 
Other  30 11 
Deceased  5 1 
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Table 5: Models (n= 237, 16 responses per person)  
 Model 1 MNL Model 2 MX Model 3 MX 
 Coeffic p Coeffic p Coefft p 
Constant (neither) 0.825 <0.0001 -0.05868 0.8539 -2.11585 <0.0001 
Stay in treatment > 3 months  0.048 <0.0001 0.04428 <0.0001 0.05986 <0.0001 
2 Days/wk of conflict (base=1) 0.17 0.0008 0.35021 0.0002 0.20763 0.0203 
4 Days/wk of family conflict -0.22 <0.0001 -0.51519 <0.0001 -0.43914 <0.0001 
6 Days/wk of family conflict -0.34 <0.0001 -0.55711 <0.0001 -0.56319 <0.0001 
Own health status (base is same)  0.84 <0.0001 1.34852 <0.0001 1.17934 <0.0001 
Contact with police 0.90 0.0002 1.91394 0.0002 1.73905 0.0002 
Donations to charity  -0.009 <0.0001 -0.01541 <0.0001 -0.01341 <0.0001 
Non-random parameters in the utility function 
Stimulants – drug of concern 
(cannabis base)     0.52078 0.0405 
Opioids – drug of concern     -0.90329 <0.0001 
Alcohol– drug of concern     -0.27808 0.2304 
Treatment Ever (yes)     -0.00151 0.9916 
Never Married      1.60015 <0.0001 
N of Dependent Children     -0.46585 <0.0001 
Dummy (1= family)  0.006 0.9547 0.01167 0.9391 0.01233 0.9374 
Distribution of Random Parameter Standard Deviations 
Constant (neither)   0.01662 0.9086 2.82213 <0.0001 
Stay in treatment > 3 months    0.04551 <0.0001 0.04238 <0.0001 
2 Days/wk of conflict (base=1)   0.60032 <0.0001 0.62508 <0.0001 
4 Days/wk of family conflict   0.60032 <0.0001 0.62508 <0.0001 
6 Days/wk of family conflict   0.60032 <0.0001 0.62508 <0.0001 
Own health status (base is same)    1.339 <0.0001 1.12753 <0.0001 
Contact with police CJS   4.0759 <0.0001 3.53855 <0.0001 
Weekly donations to charity    0.02 <0.0001 0.01683 <0.0001 
AIC 1.57  1.26  1.26  
K 9  15  21  
LLF 2986  2379  2365  
Adjusted R2 0.15  0.43  0.43  
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Table 6: Willingness to contribute to charity per week 
Attribute Model 3  95% confidence intervals 
For a 1% increase in the number of 
heroin users staying in treatment longer 
than 3 months 
$4.46 3.33 5.60 
To avoid 5 days per week of family 
discord (from 6 days to 1) 
$42.00 28.30 55.69 
For an improvement in their own health 
status  
$87.94 64.41  111.48 
For a 1% decrease in police contact $129.68 53.496  205.87 
 
 
Figure 1: Distribution of chosen willingness to contribute to charity values  
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